PTCT
PTC THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$61.53
+3.87%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$60.13
From 52W high−31.29%
Volume943977.00
Market cap$5.14B
P/E (TTM)—
P/S (TTM)5.1x
Div yield—
Key dataOct 19, 2026
Open
$60.13
From 52W high
−31.29%
Volume
943977.00
Market cap
$5.14B
ValuationView details →
P/E (Fwd)
38.5x
EV/EBITDA
20.8x
P/E (TTM)
—
RSI (14)
41.5
MomentumView details →
1D Return
+3.87%
YTD Return
−19.44%
SummaryUpdated Jun 1, 2026
PTC Therapeutics, Inc. (NASDAQ:PTCT) is a biopharmaceutical company founded in 1998 and headquartered in South Plainfield, New Jersey. The company went public in June 2013 and has evolved from a research-focused organization into a commercial-stage biopharmaceutical company with multiple marketed products. PTC specializes in discovering, developing, and commercializing treatments for rare diseases, with a particular focus on genetic disorders that affect small patient populations with high unmet medical needs.
Similar companies
Latest newsMore news →
Sangamo Therapeutics sold substantially all assets related to its gene therapy candidate ST-920 (isaralgagene civaparvovec) to PTC Therapeutics for $111 million in cash at closing, up to $100 million in contingent milestones, and assumption of specified liabilities.28d agoPTC Therapeutics agreed to acquire from Sangamo Therapeutics all rights to ST-920, an AAV gene therapy product candidate for Fabry disease, for an upfront payment of $111 million plus up to $100 million in contingent milestone payments.52d agoPTC Therapeutics announced a planned acquisition of Sangamo Therapeutics' BLA-stage ST-920 Fabry disease gene therapy program, leveraging existing regulatory and commercial infrastructure.68d ago